Integrated Biosciences unveiled a novel optogenetic screening platform combining programmable light-activation with high-throughput compound testing, enabling precise interrogation of biological targets with temporal and spatial control. Demonstrated by modulating the integrated stress response pathway, the technology identified ISR-potentiating compounds with antiviral properties, including in vivo efficacy against ocular herpesvirus. The platform addresses limitations of traditional screening by delivering selective pathway activation and clean readouts, facilitating discovery of mechanism-specific therapeutics for aging and disease-related pathways.